Background: Evidence about the use of dolutegravir (DTG) and rilpivirine (RPV) as an
antiretroviral therapy (ART) in treatment-experienced patients is scarce. Objective: To …

Few large series describe the clinical characteristics, outcomes and costs of COVID-19 in
Western countries. This cohort reports the first 1255 adult cases receiving anti-COVID-19 …

We present our experience in patients with hematologic malignancy and Pseudomonas
aeruginosa infection treated with ceftolozane-tazobactam. We performed a single-center …

Background: We report the long-term outcomes, changes in laboratory parameters, the
incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of …

Background Information and communication technologies (ICTs) are changing the
traditional health care model and redefining personalized health. ICTs offer effective …

Mould-active prophylaxis is affecting the epidemiology of invasive mycoses in the form of a
shift toward less common entities such as fusariosis. We analyze the characteristics of …

Purpose The design, implementation, and assessment of a comprehensive pharmaceutical
care program (CPCP) for hepatitis C virus (HCV)-infected patients treated with direct-acting …

The implementation of 1, 3 β-d-glucan (BDG) has been proposed as a diagnostic tool in
antifungal stewardship programs (ASPs). We aimed to analyze the influence of serum BDG …

Background: Few studies describe the use of dolutegravir (DTG)-based dual therapies
under routine clinical practice. Objectives: To report real-life data on the use of DTG-based …

Background: No previous studies exist examining the effectiveness and safety in real clinical
practice of the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+ …